Search

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

84.47 0.3

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

84.06

Massimo

84.37

Metriche Chiave

By Trading Economics

Entrata

7M

-121M

Vendite

14M

25M

EPS

-1.14

Margine di Profitto

-481.149

Dipendenti

594

EBITDA

-4.7M

-131M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+1.68% upside

Dividendi

By Acuity

Utili prossimi

5 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

63M

8.9B

Apertura precedente

84.17

Chiusura precedente

84.47

Notizie sul Sentiment di mercato

By Acuity

68%

32%

293 / 340 Classifica in Healthcare

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 ago 2026, 23:56 UTC

News

GrowGeneration reports second-quarter net sales of $43.2 million, a 5.5% increase. Shares are higher in after-market trading following the earnings announcement.

11 ago 2026, 23:56 UTC

News

Digital Realty Trust announced a quarterly dividend of $1.22 per share. Shares are trading higher in after-market hours following the announcement.

11 ago 2026, 23:56 UTC

News

UBS maintains Buy rating on Rapid7 and raises price target to $12. Shares are trading higher in after-market hours, reflecting positive investor sentiment.

11 ago 2026, 23:51 UTC

News

Codexis reported second-quarter revenues of $14.9 million, exceeding estimates. Shares are trading higher in after-market hours following the positive earnings report and guidance.

11 ago 2026, 23:51 UTC

News

Matthews International Corp names Michael J. Whitehead as CEO, succeeding Joseph C. Bartolacci. Shares are trading higher in after-market hours amid leadership transition optimism.

11 ago 2026, 23:46 UTC

News

Kilroy Realty Corp shares are higher in after-market trading following the departure of CFO Jeffrey Kuehling and the appointment of Eliott Trencher as interim CFO.

11 ago 2026, 23:46 UTC

News

Whirlpool Corp reported Q2 earnings that missed revenue and adjusted EPS expectations. Shares were roughly flat in after-market trading following the results.

11 ago 2026, 23:41 UTC

News

Clean Energy Fuels reported Q2 revenue of $106.4 million, exceeding expectations. The positive outlook for profitability growth boosted shares during after-market hours.

11 ago 2026, 23:41 UTC

News
Correlated Moves

BlackRock is joining Nvidia's $500 billion AI infrastructure initiative, though concerns about funding sustainability have contributed to lower after-market trading for the firm.

11 ago 2026, 23:41 UTC

News

Anterix shares fell in after-market trading despite a fiscal Q1 earnings beat, reporting net income of $240,000 and EPS of $0.01.

11 ago 2026, 23:41 UTC

News
Social Media

H&R Block reported fiscal 2026 revenue of $3.95 billion, exceeding expectations, and raised its dividend by 10%, contributing to a significant after-market increase.

11 ago 2026, 23:36 UTC

News

UBS upgraded Jabil Inc to Buy, maintaining a $430 price target. Shares are trading higher in after-market hours, supported by strong technical indicators.

11 ago 2026, 23:31 UTC

News

Ameresco Inc shares rose in after-market trading following strong Q2 earnings, reporting $515.5 million in revenue and raising full-year adjusted EPS guidance to $1.25.

11 ago 2026, 23:26 UTC

News
Social Media

Oracle Corp partners with Quantinuum to enhance cloud services with quantum computing. Shares are trading higher in after-market hours following the announcement.

11 ago 2026, 23:11 UTC

News
Social Media

General Motors shares declined in after-market hours following the announcement of a $4.5 billion Supplier Inventory Financing Program and plans to sell its battery joint venture stake.

11 ago 2026, 23:11 UTC

News
Social Media

Lumentum Holdings reported fiscal Q4 adjusted EPS of $3.23, exceeding estimates, and provided optimistic Q1 FY27 guidance, driving shares higher in after-market hours.

11 ago 2026, 23:06 UTC

News

Uber Technologies Inc. sold its entire stake in Serve Robotics, raising investor concerns about its delivery strategy. Shares traded lower during after-market hours.

11 ago 2026, 23:06 UTC

News

ATI Inc reported stronger second-quarter results, raising 2026 adjusted EBITDA guidance to $1.135 billion to $1.185 billion. Shares advanced in after-market hours.

11 ago 2026, 23:06 UTC

News

KKR & Co Inc has invested in Crowe Advisory LLC, enhancing service capabilities. Shares are trading higher in after-market hours following the announcement.

11 ago 2026, 23:06 UTC

News

SiTime Corp shares rose in after-market trading following a strong earnings report, highlighting 127% revenue growth and GAAP profitability.

11 ago 2026, 23:06 UTC

News

Blue Owl Capital prices $750 million in Senior Notes due 2036, aiming to repay borrowings. Shares are higher in after-market trading following the announcement.

11 ago 2026, 23:06 UTC

News

UBS initiated coverage on Century Aluminum Co with a Buy rating and a $60 price target, contributing to after-market gains.

11 ago 2026, 23:02 UTC

News

Agree Realty Corp declared a monthly cash dividend of $0.267, a 4.3% increase, contributing to a modest rise in shares during after-market hours.

11 ago 2026, 23:01 UTC

News

Siebert Financial Corp reports Q2 revenue of $31.2 million, up from $14.9 million last year. Shares are trading higher in after-market hours.

11 ago 2026, 23:01 UTC

News

Century Communities has acquired the Harbor Pointe community in Santa Ana. Shares are lower during after-market hours despite this expansion in Southern California.

11 ago 2026, 23:01 UTC

News

PagSeguro Digital shares rose in after-market hours following its Q2 earnings report, which showed a recurring net profit of 576 million reais, exceeding estimates.

11 ago 2026, 23:01 UTC

News
Event

Astronics Corporation reported second-quarter net income of $35.1 million and raised full-year revenue guidance, boosting shares higher in after-market trading.

11 ago 2026, 23:01 UTC

News

Arbor Realty Trust closed an $825 million collateralized loan obligation securitization, enhancing its balance sheet. Shares moved higher during after-market hours.

11 ago 2026, 23:01 UTC

News

Stereotaxis reported second-quarter revenue of $7.67 million, missing estimates and down from last year's $8.90 million. Shares traded roughly flat in after-market hours.

11 ago 2026, 23:01 UTC

News

Darling Ingredients announced a $150 million sale of production tax credits, boosting shares in after-market hours as investors react positively to the deal.

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

1.68% in crescita

Previsioni per 12 mesi

Media 85.56 USD  1.68%

Alto 95 USD

Basso 80 USD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

14 ratings

2

Acquista

12

Mantieni

0

Vendi

Sentiment

By Acuity

293 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat